Breast MRI Spectroscopy, Department of Defense (DOD)
The purpose of this new imaging method is to provide physicians with additional information not available with standard imaging methods. This includes information about the make up of different breast diseases. Using spectroscopy data, it may be possible to tell the difference between benign conditions of the breast from malignant tumors and provide more accurate information than can be obtained with regular MRI. Along with the MRI a new method of evaluating the images or pictures will be used. This new method is called spectroscopy and is used routinely on other parts of the body such as the prostate and brain. Pictures produced with this sequence look different than the regular MRI pictures. Performing spectroscopy on a 1.5T magnet adds another imaging sequence (another scan) to the routine MRI protocol, thus increasing exam time (extra 10-15 minutes). This study will enroll patients who are scheduled for a Magnetic Resonance Imaging (MRI) examination ordered by their primary physician.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Breast MRI Spectroscopy, Department of Defense (DOD)|
- to determine if spectroscopy of the breast can be performed and can be functional in a clinical environment for breast lesions _> 1centimeter [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
- To see if MRS can differentiate ben vs mal breast tissue with adequate specificity & sensitivity to be useful in clinical management. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
- if the data obtained can differentiate among various histologic subtypes of invasive and non-invasive breast cancers, and can be reliably analyzed and be useful to the final interpretation of the breast MRI examination. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
|Study Start Date:||February 2006|
|Study Completion Date:||May 2013|
|Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Our aim is to perform MR Spectroscopy (MRS) on 150 patients at the end of their clinically indicated routine breast MRI guided biopsy and breast MRI guided needle localization examination using a software package from General Electric Medical Systems (Milwaukee,WI). This will add time to the routine examination but will not involve additional injections of contrast. We will analyze the spectroscopic data to determine if benign lesions can be reliably differentiated from malignant ones. The MR Spectroscopy (MRS) will be administered at Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY,NY 10021.
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Sandra Brennan, MD||Memorial Sloan-Kettering Cancer Center|